Pharmacokinetics of N-acetylcysteine in man

  title={Pharmacokinetics of N-acetylcysteine in man},
  author={Lars Borgstr{\"o}m and Bertil K{\aa}gedal and Otto Paulsen},
  journal={European Journal of Clinical Pharmacology},
SummaryN-Acetylcysteine was given intravenously and as three fast dissolving and one slow-release formulation, on separate occasions, as a single dose of 600 mg to 10 fasting (5 men and 5 women) healthy volunteers. Blood and urine were sampled for the following 12 h.Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg. Volume of distribution was 0.33 l/kg, consistent with distribution mainly to extracellular water. The late elimination half-life was 2.27 h and… 
Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine
SummaryThe pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers.According to a randomized
Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats.
Despite the low bioavailability, plasma concentrations of NAC after oral administration at 100 mg/kg may be effective in the treatment of chronic diseases.
The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage
The dosage schedule for intravenous N-acetylcysteine should probably be modified since adverse reactions invariably occur early when plasma concentrations are at their highest, and liver damage was prevented just as effectively at the lowest as at the highest Cmax.
Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise
NAC can be given to healthy exercising men by intravenous infusion and to the plasma concentrations seen in this study with minimal adverse effects due to the drug.
Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
The pharmacokinetic characteristics of NAC are similar in healthy Chinese and Caucasian individuals after single and repeated administration and NAC has a favourable tolerability profile.
Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration
The data show that NAC leads to a marked increase in circulating Cysteine, in part by reacting with cystine and thereby forming mixed disulphides with cysteine and releasing free cysteined as shown in vitro.
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.
Findings indicate that the total clearance of oral NAC is significantly reduced in ESRD patients, leading to marked increases in systemic exposure, and suggest that NAC may have a limited role in the chronic treatment of oxidative stress-related illness.
N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
Clinical studies of N-acetylcysteine in the prevention of RCIN have yielded highly mixed results; five were dramatically positive, and eight others had no demonstrable efficacy at all; the following will review the individual studies, attempt to reconcile the divergent results, and propose future research needs.
N-acetylcysteine overdose after acetaminophen poisoning
Considering the similarity between some of the clinical symptoms of acetaminophen overdose and NAC overdose, it is vitally important for the administration phases and checking of the patient’s symptoms to be carried out attentively and cautiously.


Pharmacokinetics of bendroflumethiazide after low oral doses
The pharmacokinetics of bendroflumethiazide after oral administration of 1.25, 2.5, and 5.0 mg were studied in nine healthy male volunteers and the urinary sodium concentration was doubled after bendro FLM intake, but the urinary potassium concentration remained almost constant.
Pharmacokinetics of Oral Acetylcysteine: Absorption, Binding and Metabolism in Patients with Respiratory Disorders
SummaryThe fate of an oral 100mg dose of 35S-acetylcysteine, a mucolytic agent, was studied in 10 patients with respiratory disorders, 5 of whom underwent pneumonectomy or lobectomy a few hours after
Effect of activated charcoal administration on acetylcysteine serum levels in humans.
The data suggest that acetylcysteine absorption is not impaired by activated charcoal administration, which conflicts with previously published in vitro data; therefore, it is recommended that activated charcoal should not be administered concomitantly with acetyl Cysteine as a usual procedure until more data are available.
Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning.
Intravenous acetylcysteine was more effective than cysteamine and methionine and noticeably free of adverse effects and is the treatment of choice for paracetamol poisoning.
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo.
Exogenous N-acetylcysteine does not form significant amounts of conjugate with the reactive metabolite of acetaminophen in the rat in vivo but increases glutathione synthesis, thus providing more substrate for the detoxification of the reactive metabolismite in the early phase of an acetamophen intoxication when the critical reaction with vital macromolecules occurs.
High-performance liquid chromatographic assay for N-acetylcysteine in plasma and urine.
In a multistep extraction procedure, which is slightly modified for the N-acetylcysteine assay in urine, the limits of sensitivity for the plasma and urine assays were found to be congruent to 60 ng/mL and congruents to 200 micrograms/mL, respectively.
Determination of N-acetyl-L-cysteine in biological fluids.
A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
The effects of acetylcysteine 600 mg daily, 3 days a week for 6 months, and a placebo have been compared in a double-blind controlled trial to suggest that the mucolytic may be useful as an alternative to long-term antibiotic prophylaxis, or to complement brief courses of antibiotics.
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
The exacerbation rate was significantly lower in the acetylcysteine group in which 40% of the patients remained free from exacerbations compared to 19% in the placebo group.